Scribe Therapeutics Inc. (SCTX) P/B ratio
There is no P/B ratio history on record here for Scribe Therapeutics Inc. (SCTX). Figures as of 18 Nov 2026, 10:35 UTC, from Yahoo Finance.
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/B ratio needs at least 3 fiscal years; none is on record here for Scribe Therapeutics Inc.. Nothing is estimated to fill the gap. What is on record is in the table below.
Scribe Therapeutics Inc. P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Book value per share |
|---|---|---|---|---|
| 2025 | — | — | -$8.16 | |
| 2024 | — | — | -$7.16 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Scribe Therapeutics Inc., figure by figure
- Scribe Therapeutics Inc. market cap
- Scribe Therapeutics Inc. revenue
- Scribe Therapeutics Inc. earnings
- Scribe Therapeutics Inc. earnings per share (EPS)
- Scribe Therapeutics Inc. P/E ratio
- Scribe Therapeutics Inc. P/S ratio
- Scribe Therapeutics Inc. free cash flow
- Scribe Therapeutics Inc. operating margin
- Scribe Therapeutics Inc. dividend
- Scribe Therapeutics Inc. shares outstanding
- Scribe Therapeutics Inc. total debt
- Scribe Therapeutics Inc. cash on hand
- Scribe Therapeutics Inc. total assets
- Scribe Therapeutics Inc. return on equity (ROE)
- Scribe Therapeutics Inc. return on invested capital (ROIC)
Scribe Therapeutics Inc. (SCTX) overview: price, valuation and scorecard
Scribe Therapeutics Inc. P/B ratio: questions and answers
How is Scribe Therapeutics Inc.'s P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Scribe Therapeutics Inc. (SCTX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SCTX/pb-ratio
Underlying data: Yahoo Finance.